Kalytera to Acquire Stero Biotechs, Ltd.
March 05, 2020 08:00 ET
|
Kalytera Therapeutics Inc.
Acquisition Will Bring Kalytera Multiple Additional CBD Pharmaceutical Programs New Product Development Programs Will Address Large Commercial Opportunities in Steroid Sparing Kalytera Also...
Kalytera Announces Modification to Sale Period for Shares Issued under Payments Agreement
February 19, 2020 22:52 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, Calif. and TEL AVIV, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced a...
Kalytera Completes Share Issuance under Payments Agreement
February 18, 2020 23:46 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has...
Kalytera Announces New Payments Agreement with the Salzman Group of Israel
February 07, 2020 17:54 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has...
Kalytera Announces Notice of Allowance of Additional U.S. Patent for Prevention and Treatment of Graft Versus Host Disease
February 05, 2020 08:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the United...
Kalytera Announces Intention to Seek Amendment of Secured Convertible Debentures Due December 2019
December 20, 2019 18:57 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has not...
Kalytera Announces Extension of Maturity Date of Promissory Note
December 16, 2019 08:00 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that, in...
Kalytera Reports Third Quarter 2019 Financial Results
December 02, 2019 08:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, Calif. and TEL AVIV, Israel, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial...
Published Studies Provide Further Support For Kalytera’s Program Evaluating CBD in GVHD
November 22, 2019 08:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that research...
Kalytera Announces Closing of Final Tranche of Private Placement of Common Shares and Common Share Purchase Warrants and Amendments to Secured Convertible Debenture Units
October 30, 2019 22:10 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that it has...